Jasper Therapeutics, Inc. announced promising preliminary results from its BEACON Phase 1b/2a study of briquilimab, an experimental therapy targeting mast cell-driven diseases like chronic ...
Jasper Therapeutics will present preliminary data from the BEACON study of briquilimab, which could enhance the visibility and interest in their novel antibody therapy. The inclusion of Dr. Thomas B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback